Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082850 | 0.86 | HTT (0.44) | HTTKMT2AMEN1MAPTCYP4Z1 | |
| SCHEMBL693860 | 0.85 | SLC7A5 (0.54) | HTTKMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12440456 | 0.85 | MEN1 (0.54) | HTTKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL30967793 | 0.85 | CYP4F2 (0.53) | MAPTCYP4Z1ALDH1A1SYK | |
| Hydrochloric Acid SCHEMBL2082848 | 0.85 | MAPT (0.46) | HTTKMT2AMEN1MAPTCYP4Z1 | |
| SCHEMBL68412 | 0.85 | L3MBTL1 (0.50) | HTTKMT2AMEN1MAPTCYP4Z1 | |
| SCHEMBL6366473 | 0.84 | DHODH (0.44) | HTTKMT2AMEN1MAPTCYP4Z1 | |
| SCHEMBL12440452 | 0.82 | POLB (0.50) | SMN1; SMN2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL11629505 | 0.81 | TP53 (0.48) | HTTKMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL5089369 | 0.81 | MAPT (0.43) | HTTKMT2AMEN1MAPTCYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-6838478-B2 | Amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| CN-1129604-C | Amino acid derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 2003-12-03 | — | — | CN | disclosed |
| EP-0910573-B1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-14 | — | — | US | disclosed |
| US-6255301-B1 | CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-07-03 | — | — | US | disclosed |
| CN-1226895-A | Amino acid derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 1999-08-25 | — | — | CN | disclosed |
| EP-0910573-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997046577-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-12-11 | — | — | WO | disclosed |
| US-4230703-A | ANALGESICS; ANTIINFLAMMATORY AGENTS | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | F2, SERPINC1, FGB | HTT 3385/4885KMT2A 3943/4885MEN1 2803/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | HTT 106/4885KMT2A 2708/4885MEN1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.